Lookie what came in to my e-mail box overnight after yesterday's post about the hypotrichosis treatment, Latisse® brand of bimatoprost.
Hmm...I have a few ideas who might have sent this (no profanity, so it wasn't Comrade PhysioProf). And very interesting that this comes just a week before FDA holds an opening hearing entitled, "Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools. For your information, here's the PDF schedule courtesy of colleague John Mack - Pharma Marketing Blog and @pharmaguy. John is currently running a survey in his masthead to solicit…
latisse
I am running out of eyelash puns having written at least six posts since the summer of 2007 on a class of anti-glaucoma drugs that have been harnessed for their cosmetic side effect: promotion of eyelash growth. Bimatoprost (Lumigan®) and latanoprost (Xalatan®) are members of the prostamide class of drugs that can manage some forms of glaucoma by reducing intraocular pressure. When administered as eye drops, the drugs mimic the effect of endogenous prostaglandin PGF2α, acting as a local hypotensive to promote outflow of aqueous humor from the eye through the trabecular meshwork.
Invoking the…